Table 4.
Mean (s.e. mean) serum lipid concentrations (mg dl−1) on day 14 after oral administration of simvastatin, ezetimibe, the coadministration of simvastatin and ezetimibe, or placebo (Studies 1 and 2).
| Treatment | Day | LDL-C | TC | HDL-C | TG |
|---|---|---|---|---|---|
| Study 1 | |||||
| Placebo, n = 11 | Baseline | 164.0 (6.6) | 241.5 (7.9) | 49.7 (3.5) | 118.5 (10.4) |
| Day 14 | 158.3 (9.4) | 229.4 (9.9) | 39.0 (2.8) | 146.1 (13.0) | |
| SIM 10 mg, n = 12 | Baseline | 167.5 (8.9) | 247.3 (7.3) | 44.8 (2.5) | 138.7 (12.1) |
| Day 14 | 108.4 (6.5) | 176.8 (7.5) | 41.0 (2.5) | 110.6 (11.4) | |
| SIM 10 mg + EZE 0.25 mg, n = 11 | Baseline | 177.1 (12.7) | 257.9 (13.6) | 41.4 (2.8) | 134.6 (17.0) |
| Day 14 | 109.3 (10.8) | 177.3 (9.9) | 36.9 (2.3) | 127.1 (12.4) | |
| SIM 10 mg + EZE 1 mg, n = 12 | Baseline | 177.3 (12.5) | 267.0 (12.8) | 43.5 (3.3) | 167.7 (17.4) |
| Day 14 | 104.5 (6.8) | 180.1 (8.7) | 38.8 (2.3) | 144.3 (19.1) | |
| SIM 10 mg + EZE 10 mg, n = 12 | Baseline | 171.4 (7.3) | 245.1 (9.5) | 43.5 (2.1) | 126.4 (7.1) |
| Day 14a | 82.9 (6.5) | 152.3 (7.3) | 37.3 (2.1) | 121.5 (17.2) | |
| Study 2 | |||||
| SIM 20 mg, n = 8 | Baseline | 157.8 (6.4) | 242.1 (9.0) | 44.3 (1.9) | 153.8 (12.4) |
| Day 14 | 93.0 (6.2) | 176.1 (7.2) | 37.6 (1.7) | 134.9 (13.7) | |
| EZE 10 mg, n = 8 | Baseline | 168.5 (9.5) | 243.8 (10.4) | 45.5 (3.5) | 134.4 (13.7) |
| Day 14 | 112.4 (9.6) | 197.4 (14.1) | 38.8 (3.1) | 148.6 (41.1) | |
| SIM 20 mg + EZE 10 mg, n = 8 | Baseline | 183.4 (11.9) | 265.3 (14.0) | 46.6 (2.5) | 151.9 (20.8) |
| Day 14 | 77.0 (9.7) | 150.9 (12.8) | 39.8 (1.8) | 124.6 (17.5) | |
s.e. mean, standard error; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; SIM, simvastatin; EZE, ezetimibe.
a
n = 11.